TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15385012
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg x kg(‐1) levobupivacaine
Study: 15385012
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg(‐1) levobupivacaine
Study: 11203270
Drug: Mini-tablets (filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-tablets (filled into hard gelatin capsules)
Study: 11203270
Drug: Commercial matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial matrix formulation (Ibu-Slow 600)
Study: 1778222
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous glucose infusion [44.4 mumol kg‐1 body weight (bw) min‐1]
Study: 27220987
Drug: ACS administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACS administration within 7 days of delivery
Study: 23904492
Drug: Dopaminergic modulation
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dopaminergic modulation (L-DOPA)
Study: 16309769
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n = 53)
Study: 8154035
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) 800 mg orally or 400 mg i.v. q.i.d. for 12 weeks after transplantation or 6 weeks after any antirejection therapy
Study: 8154035
Drug: Ganciclovir (GCV)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (GCV) 5 mg/kg/12 hr i.v. for 7 days after transplant or after any antirejection therapy plus human immune globulin (HIg) 100 mg/kg i.v. administered on days 1, 4, and 7 after transplant or after any antirejection therapy
Study: 29221717
Drug: Metformin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin combined with therapeutic lifestyle changes (TLC)
Study: 25534864
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of intravenous and topical tranexamic acid (TXA)
Study: 16801182
Drug: GosFos (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GosFos (1 g/100 mL)
Study: 10995002
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (L-asparaginase and intermediate-dose methotrexate)
Study: 10995002
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (cytarabine and intermediate-dose methotrexate)
Study: 8810562
Drug: MLPA test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLPA test for detection of anti-PGL-1 antibodies
Study: 8403676
Drug: Debridement and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement and conventional parenteral systemic antibiotic therapy
Study: 3527946
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (400 mg 17-1A immunoglobulin, single dose, intravenous)
Study: 3527946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of monoclonal antibody and F.A.M. chemotherapy (5-fluorouracil, adriamycin, mitomycin)
Study: 3527946
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (after 8-week cycle of F.A.M. chemotherapy)
Study: 3527946
Drug: F.A.M. chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: F.A.M. chemotherapy
Study: 24618153
Drug: Chemotherapy arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy arm (T-ET)
Study: 20799126
Drug: Hypnosis (year-long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (year-long weekly group intervention)
Study: 18855808
Drug: Focus on
Normalized name: Menthol 2.1 g in 60 mL TOPICAL GEL [Biocool Focus On]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focus on Families intervention (treatment-as-usual plus intervention)
Study: 12597931
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg administered intravenously 5 minutes before ESWL)
Study: 12597931
Drug: Music chosen
Normalized name: LANCET,CHOSEN DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music chosen by the patients listened to with a headset during treatment
Study: 11291604
Drug: Ganciclovir pre-emptive
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir pre-emptive treatment
Study: 1482267
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (N = 146)
Study: 27433356
Drug: Years since
Approvals — FDA: no, EMA: no, PMDA: no
Description: Years since treatment
Study: 25275218
Drug: Beraprost (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost (80 μg twice a day orally)
Study: 22510238
Drug: tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.4 mg/day plus vardenafil 10 mg/day
Study: 22510238
Drug: tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.4 mg/day
Study: 21095265
Drug: 24 months
Normalized name: influenza virus vaccine ts 2015-2016 (6-24 months)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 months of clopidogrel therapy
Study: 21095265
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of clopidogrel therapy
Study: 18646528
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (16.7 mg/d)
Study: 18646528
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (8.4 mg/d)
Study: 18646528
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (5.6 mg/d)
Study: 18646528
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (0.0 mg/d)
Study: 18646528
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (VE 5 mg/d)
Study: 12486649
Drug: hemoglobin raffimer
Normalized name: hemoglobin raffimer
DrugBank: Hemoglobin raffimer (DB13658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemoglobin raffimer (250 mL, 500 mL, or 750 mL)
Study: 12486649
Drug: hemoglobin raffimer
Normalized name: hemoglobin raffimer
DrugBank: Hemoglobin raffimer (DB13658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemoglobin raffimer (750 mL)
Study: 10367952
Drug: Vaqta 50
Normalized name: Vaqta 50 UNT/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaqta 50 U/dose
Study: 10367952
Drug: Vaqta 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaqta 100 U/dose
Study: 10367952
Drug: Havrix 1440
Normalized name: Havrix 1440 UNT/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix 1440 U/dose
Study: 2350052
Drug: Multicomponent endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent endotracheal anesthesia with neuroleptanalgesia and cardiopulmonary bypass, postoperative analgesia with non-narcotic and narcotic analgesics
Study: 2350052
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia into upper chest segments with trimecaine + adrenaline and low morphine doses
Study: 31761527
Drug: Received depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received depression help-seeking message twice
Study: 19579092
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment entry within four months
Study: 19579092
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drug use
Study: 19579092
Drug: Heroin use
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin use among non-treatment entrants
Study: 10841243
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin 6 h postoperatively
Study: 10841243
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin 24 h postoperatively
Study: 9506008
Drug: Testosterone transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone transdermal system applied to upper buttocks
Study: 9506008
Drug: Testosterone transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone transdermal system applied to upper arm
Study: 9506008
Drug: Testosterone transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone transdermal system applied to back
Study: 8432275
Drug: lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 1.5 mg/kg
Study: 3099487
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nitroglycerin per day
Study: 3099487
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nitroglycerin per day
Study: 20009790
Drug: Preoperative sizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative sizing with silicone implant samples
Study: 19213351
Drug: Integrative Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Chinese and Western medicine treatment including Chinese recipe decoction (500 mL for hip bathing 5-10 min every night) and local application of Jingan oil (twice daily) for 2 months.
Study: 8595172
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of ZD1033 daily for 10 days
Study: 8595172
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of ZD1033 daily for 14 days
Study: 8595172
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of ZD1033 daily for 14 days
Study: 6119492
Drug: Preoperative parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative parenteral nutrition (PPN) for 10 days
Study: 31494273
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of oxytocin nasal spray
Study: 27492419
Drug: Nutrient-dense oral
Normalized name: Votrient Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient-dense oral nutritional supplement (ONS) containing high protein and β-hydroxy-β-methylbutyrate
Study: 27492419
Drug: Nutrient-dense oral
Normalized name: Votrient Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient-dense oral nutritional supplement (ONS)
Study: 23212610
Drug: CR665 (0.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR665 (0.36 mg/kg, intravenous)
Study: 21654521
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg intravenously on day 1 of the 2‐week cycle and IFN‐α thrice weekly at 5 MU/m subcutaneously during cycle 1, increased to 10 MU/m during cycle 2.
Study: 21654521
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and IFN‐α combination therapy
Study: 10627736
Drug: Gentamicin 6
Normalized name: gentamicin 60 mg/50 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 6 mg/kg once daily
Study: 10627736
Drug: Gentamicin 5
Normalized name: gentamicin 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 5 mg/kg divided into twice daily doses
Study: 8654073
Drug: 3 concentrations
Normalized name: docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 concentrations of Dimethylsulfoxide (DMSO) and 0.2 mol/l NaOH applied for 5 minutes
Study: 7255513
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg fenoprofen
Study: 7255513
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg fenoprofen
Study: 28867717
Drug: Double-dose TWHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose TWHF (DTW)
Study: 28867717
Drug: Conventional-dose TWHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose TWHF (CTW)
Study: 17599843
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg of vaginal misoprostol on treatment day 1
Study: 17599843
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of misoprostol if expulsion was incomplete on day 3
Study: 15240627
Drug: Variable infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable infusion rate (3 kcal/min for the first 15 min, then 0.71 kcal/min for the next 105 min)
Study: 15240627
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion rate (1 kcal/min from t = 0 to 120 min)
Study: 15240627
Drug: Variable infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable infusion rate
Study: 15240627
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion rate
Study: 12182779
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (without mesh)
Study: 7661121
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (SPE; 12.4 g/d)
Study: 7661121
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (SPE; 3 g/d)
Study: 799564
Drug: Propranolol or
Normalized name: propranolol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol or Pindolol (acute and chronic administration)
Study: 28287798
Drug: Cognitive anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive anxiety sensitivity treatment (CAST) plus cognitive bias modification for anxiety sensitivity (CBM-I)
Study: 25953971
Drug: Home-based diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based diabetes symptom self-management education (8 weekly in-home sessions + 8 biweekly support calls)
Study: 17923131
Drug: Standard IVF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IVF treatment
Study: 7703814
Drug: Life Education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Education drug education programme (5 consecutive years)
Study: 7703814
Drug: Conventional school-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional school-based drug education (control group)
Study: 1013671
Drug: mexiletine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexiletine (250 mg 8‐hourly)
Study: 26916879
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 to 2.4 mg/g nicotine, 9 to 13 mg tar)
Study: 26916879
Drug: Moderate Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate Nicotine Content (5.2 mg/g nicotine, 9 mg tar)
Study: 26916879
Drug: Normal Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Nicotine Content (NNC) cigarettes (15.8 mg/g, 9 mg tar)
Study: 24626998
Drug: CRT-D implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D implantation with GFR <60 mL/min/1.73 m²
Study: 24626998
Drug: CRT-D implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D implantation with GFR ≥60 mL/min/1.73 m²
Study: 15729065
Drug: IPCfoot+calf and
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPCfoot+calf and aspirin (75 mg)
Study: 15729065
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg) alone
Study: 9748878
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of berodual sol 3.5 ml/day (1.75 mg phenoterol + 0.875 mg ipratropium bromide)
Study: 9748878
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of berodual sol 7 ml/day (3.5 mg phenoterol + 1.75 mg ipratropium bromide)
Study: 7853434
Drug: Gentamicin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 30 mg/kg/day
Study: 7853434
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid 60 mg/kg/day
Study: 31751936
Drug: Delayed-release sodium
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release sodium bicarbonate (DEL)
Study: 27987228
Drug: Xen2174 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xen2174 2.5 mg
Study: 25204316
Drug: 2.9 g
Normalized name: ZINC OXIDE 12.9 g in 100 g TOPICAL LOTION [UV Skin Recovery SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.9 g of eicosapentaenoic acid plus docosahexaenoic acid for 12 weeks
Study: 14760802
Drug: Blind subacromial
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind subacromial injection of 20 mg triamcinolone (Group 1, n = 20)
Study: 14760802
Drug: Sonographic guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographic guided injection of 20 mg triamcinolone (Group 2, n = 21)
Study: 9503046
Drug: 0.5 microgram
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microgram calcitriol plus 500 mg calcium daily for 6 months
Study: 9503046
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU cholecalciferol and 1000 mg calcium daily for 6 months
Study: 7995063
Drug: Topical 0.02%
Normalized name: tretinoin topical 0.02% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.02% mitomycin C for 5 min at the completion of surgery
Study: 25953327
Drug: Venlafaxine (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (375 mg/day)
Study: 25953327
Drug: Imipramine (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (blood level 200-300 ng/ml)
Study: 22470921
Drug: Vatreptacog alfa
Normalized name: Vatreptacog alfa
DrugBank: Vatreptacog alfa (DB12409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatreptacog alfa (5, 10, 20, 40, and 80 µg kg(‐1))
Study: 22470921
Drug: Recombinant FVIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FVIIa (rFVIIa) at 90 µg kg(‐1)
Study: 10716460
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose heparin (300 IU/kg)
Study: 10716460
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (0 or 5,000 IU)
Study: 9184580
Drug: Adenosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (2 mg/min)
Study: 8263864
Drug: Postoperative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative fluid instillation (1-2 L)
Study: 2993733
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (35 g)
Study: 29508539
Drug: Therapist-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-delivered cognitive behavioural therapy
Study: 29508539
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioural therapy
Study: 27170728
Drug: OJ with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OJ with 5.5 g added orange pomace fiber (OPF)
Study: 24950270
Drug: Perineal low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineal low rectal dissection
Study: 24950270
Drug: Abdominal low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal low rectal dissection
Study: 19829124
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (1200 mg intravenously during the procedure and 1200 mg orally two times daily for the next 48 h after percutaneous coronary intervention)
Study: 16137113
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg docosahexaenoic acid (DHA)
Study: 16137113
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg 5‐methyl‐tetra‐hydro‐folate (5‐MTHF)
Study: 16137113
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 500 mg DHA and 400 mg 5‐MTHF
Study: 11875284
Drug: Stimulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant treatment
Study: 373852
Drug: Salbutamol given
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol given intravenously (500 microgram injection)
Study: 373852
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (IPPB and intravenous)
Study: 30112581
Drug: Neural mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural mobilization (NM) exercises targeting the median, musculocutaneous, femoral, and saphenous nerve, performed twice daily for 4-8 weeks.
Study: 27506836
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy in women aged 65-79 years